Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05176626 · ClinicalTrials.gov registry record · Phase 4
Long-term Effectiveness of the Antiobesity Medication Phentermine
A Phase 4 study of Obesity and Lifestyle, Healthy, sponsored by Wake Forest University Health Sciences.
- Active
- Registry status
- Phase 4
- Development phase
- 870
- Enrollment target
- 4
- Study locations
NCT05176626: Active Phase 4 study of Obesity and Lifestyle, Healthy, sponsored by Wake Forest University Health Sciences.
NCT05176626 is a Phase 4 study of Obesity and Lifestyle, Healthy that is active but no longer recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 870 participants, roughly in line with the 818-participant average among 1,053 other Obesity trials with a reported enrollment target. The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05176626, a Phase 4 study of Obesity and Lifestyle, Healthy, is active but no longer recruiting, sponsored by Wake Forest University Health Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 870 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this research study is to understand the long-term effects of the drug phentermine on weight, blood pressure, other health outcomes, and safety. Phentermine has been approved by the US Food and Drug Administration (FDA) for weight management since 1959, but it has not been approved for long-term use (i.e., treatment lasting more than 12 weeks). This trial is designed to learn about the long-term effects of phentermine for up to 2 years because obesity is a chronic disease and expert guidelines recommend long-term use of anti-obesity medications as one treatment option.
Primary Outcome
The primary outcome for efficacy will be percent weight loss at 24 months of follow-up, relative to body weight (kg) at randomization.
Conditions Studied
Interventions
- BEHAVIORAL Online Lifestyle Behavioral Therapy
- DRUG Phentermine Hydrochloride 8 MG
Study Locations (4)
California
- Kaiser Permanente Southern California - Los Angeles
Minnesota
- HealthPartners Institute - Saint Louis Park
North Carolina
- Atrium Health Wake Forest Baptist Weight Management Center - Winston-Salem
Texas
- UT Center for Obesity Medicine and Metabolic Performance - Bellaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 870 participants |
| Start Date | 2022-06-30 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
What the registry record for NCT05176626 still lists
NCT05176626 is an interventional study that assigns participants to a tested intervention. The registered 870 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 818-participant average among 1,053 other Obesity trials with a reported enrollment target.
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Online Lifestyle Behavioral Therapy is the first listed.
NCT05176626 reports a single indexed study location in California, Minnesota, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05176626 about?
NCT05176626 is a clinical study titled "Long-term Effectiveness of the Antiobesity Medication Phentermine". The purpose of this research study is to understand the long-term effects of the drug phentermine on weight, blood pressure, other health outcomes, and safety. Phentermine has been approved by the US Food and Drug Administration (FDA) for weight management since 1959, but it has not been approved fo...
What is the current status of trial NCT05176626?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 870 participants. The study started on 2022-06-30. Estimated completion is 2026-12-31.
What conditions does trial NCT05176626 study?
This clinical trial studies the following conditions: Obesity, Lifestyle, Healthy, Obesity; Drug.
What interventions are being tested in trial NCT05176626?
The interventions under investigation include: Online Lifestyle Behavioral Therapy (BEHAVIORAL), Phentermine Hydrochloride 8 MG (DRUG).
Who is sponsoring clinical trial NCT05176626?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05176626 being conducted?
This trial has 4 study locations across California, Minnesota, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05176626's enrollment target sits among peer trials
870 86th of 1053 higher than 968 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04097145 · 870 participants · NA
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
- NCT06822790 · 869 participants · Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- NCT06077760 · 868 participants · Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- NCT04933552 · 867 participants
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI